{"id":"NCT02980042","sponsor":"University of Colorado, Denver","briefTitle":"Safety of Switching From Rituximab to Ocrelizumab in MS Patients","officialTitle":"Evaluating the Tolerability and Safety Profile of Switching From Rituximab to Ocrelizumab: A Real World Evaluation of Patients With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-01-01","primaryCompletion":"2019-03-06","completion":"2019-03-06","firstPosted":"2016-12-02","resultsPosted":"2020-01-14","lastUpdate":"2021-07-21"},"enrollment":200,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Ocrelizumab","otherNames":["Ocrevus"]},{"type":"DRUG","name":"Rituximab","otherNames":["Rituxan"]}],"arms":[{"label":"Switching Group","type":"EXPERIMENTAL"},{"label":"Comparator Group","type":"ACTIVE_COMPARATOR"}],"summary":"This is a prospective between and within group observational study to determine differences in tolerability, immunogenicity and safety related outcomes for 100 multiple sclerosis (MS) patients who have been administered at least two infusions of rituximab, six months apart and are willing to be switched to ocrelizumab compared to a 100 patients who are continuing on rituximab as a comparison cohort from the clinic population treated as part of clinical care.","primaryOutcome":{"measure":"Proportion of Infusions With >= 1 IRR Between the Switching and Comparator Groups","timeFrame":"Day 1, Day 15, Week 24","effectByArm":[{"arm":"Switching Group","deltaMin":10,"sd":null},{"arm":"Comparator Group","deltaMin":14,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1996"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":18,"exclusionCount":10},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":100},"commonTop":["Upper Respiratory Infection","Headache","Nausea","Numbness"]}}